

BETULIN DERIVATIVES

Prepared by:

CPL Business Consultants

The Manor House, Howbery Park, Wallingford, Oxfordshire, OX10 8BA

Tel: +44 1491 822 844, info@cplconsult.com, www.cplconsult.com

Mattias Bergström
Dr Michael Lee
Dr Esther Hunter
Dr Robert Harwood
Dr Steve Lisansky

July 2013

STRATEGIES TO GROW YOUR BUSINESS

TABLE OF CONTENTS

OBJECTIVE	1
BACKGROUND	1
SCOPE	2
METHOD	2
PRINCIPAL FINDINGS	3
PROPERTIES AND SOURCES	3
OVERVIEW OF BETULIN/BETULIN DERIVATIVE’S MARKETS	3
RESEARCH AND PATENTS	4
PHARMACEUTICALS	8
FINE CHEMICALS	15
DIETARY SUPPLEMENTS	17
COSMETICS	19
CONCLUSIONS	23
OVERVIEW OF BETULIN/BETULIN DERIVATIVES MARKETS	23
FINE CHEMICALS AND PHARMACEUTICALS	23
DIETARY SUPPLEMENTS	26
COSMETICS	26
RECOMMENDATIONS	29
COSMETICS	29
PHARMACEUTICALS & FINE CHEMICALS	29
DIETARY SUPPLEMENTS	30
BETULIN AND DERIVATIVES	31
TERPENES BACKGROUND	31
LUPEOL	32
BETULIN	32
BETULINIC ACID	33
<i>Isolation of Betulinic Acid</i>	34
<i>Synthesis of Betulinic Acid</i>	34
SCIENTIFIC RESEARCH	36
BETULIN	36
<i>Actinic keratosis</i>	36
<i>Antiphlogistic Activity</i>	36
<i>Herpes</i>	37
BETULINIC ACID	39
<i>Actinic keratosis</i>	40
<i>Antiphlogistic Activity</i>	41
<i>Cancer</i>	41
<i>HIV</i>	50
<i>Other</i>	57
LUPEOL	59
<i>Antiphlogistic Activity</i>	59
<i>Other</i>	61
PATENTS	61
MANUFACTURING OF BETULIN	61
APPLICATIONS OF BETULIN	62
MANUFACTURING OF BETULINIC ACID	62
APPLICATIONS OF BETULINIC ACID	63
MANUFACTURING OF LUPEOL	64
APPLICATIONS OF LUPEOL	64

POTENTIAL OF BETULIN AND DERIVATIVES IN PHARMACEUTICALS	66
OVERVIEW	66
OPPORTUNITIES.....	68
CONTACT OVERVIEW	73
POTENTIAL PARTNERS	75
COMPANIES WITH PHARMACEUTICAL RESEARCH ACTIVITIES RELATING TO BETULIN, BETULINIC ACID OR LUPEOL	78
ADDITIONAL MATERIAL	84
HIV.....	84
<i>Markets & Trends</i>	84
<i>Products</i>	86
<i>Statistics</i>	89
CANCER	89
<i>Markets and Trends</i>	89
<i>Products</i>	91
<i>Statistics</i>	92
MALIGNANT MELANOMA	95
<i>Markets and Trends</i>	95
<i>Products</i>	96
<i>Statistics</i>	100
ACTINIC KERATOSIS	110
<i>Market and Trends</i>	110
<i>Products</i>	111
<i>Statistics</i>	112
HERPES	115
<i>Market and Trends</i>	115
<i>Products</i>	117
<i>Statistics</i>	120
POTENTIAL OF BETULIN AND DERIVATIVES IN COSMETICS/COSMECEUTICALS	123
THE CHARACTERISTICS OF THE COSMETICS/PERSONAL CARE AND SUPPLY INDUSTRY	123
OPPORTUNITIES IN COSMETICS/COSMECEUTICALS	124
BETULIN AND DERIVATIVES AS COSMECEUTICALS	126
CONTACT OVERVIEW	127
POTENTIAL PARTNERS	130
COMPANIES IN THE BIOACTIVE SUPPLY BUSINESS (EXAMPLES).....	134
COMPANIES WITH CONSUMER PRODUCTS CONTAINING BETULIN, BETULINIC ACID OR LUPEOL	145
FORMULATORS USING BETULIN, BETULINIC ACID OR LUPEOL AS AN INGREDIENT	162
COMPANIES WITH COSMETIC RESEARCH ACTIVITIES RELATING TO BETULIN, BETULINIC ACID OR LUPEOL...	181
POTENTIAL OF BETULIN AND DERIVATIVES IN DIETARY SUPPLEMENTS	186
OPPORTUNITIES.....	186
CONTACT OVERVIEW	188
POTENTIAL PARTNERS	188
COMPANIES WITH PRODUCTS CONTAINING BETULIN, BETULINIC ACID OR LUPEOL	197
POTENTIAL OF BETULIN AND DERIVATIVES IN FINE CHEMICALS	206
OPPORTUNITIES.....	206
CONTACT OVERVIEW	207
POTENTIAL PARTNERS	207
COMPANIES CURRENTLY SUPPLYING TRITERPENE DERIVATIVES AS FINE CHEMICALS	210
OVERVIEW OF THE CURRENT MARKET FOR TRITERPENE DERIVATIVES.....	213
MARKET.....	213
CURRENT PLAYERS, PRODUCTS AND PRICES	213
<i>Manufacturers</i>	220
<i>Processors and Traders</i>	248
OVERVIEW OF THE GLOBAL PHARMACEUTICAL INDUSTRY.....	262
MARKET.....	262

MARKET TRENDS	265
THE DRUG DEVELOPMENT PROCESS	267
<i>Cost of developing a new medicine</i>	267
<i>Drug development and the conduct of medical research</i>	268
<i>Clinical trials</i>	270
<i>Success rates in Drug Development</i>	273
<i>The promotion of drugs</i>	273
<i>Market Penetration for New Drugs</i>	274
<i>Historical Data</i>	275
INTELLECTUAL PROPERTY PROTECTION	276
<i>Procedures for Drug Approval</i>	277
PLAYERS	277
<i>12 companies</i>	
THE PHARMACEUTICAL INDUSTRY BY REGION	294
<i>The US Pharmaceutical Industry</i>	294
<i>The European Pharmaceutical Industry</i>	295
<i>US vs. Europe - Competitive Comparison</i>	317
<i>The Pharmaceutical Industry in the ROW</i>	319
OVERVIEW OF GLOBAL FINE CHEMICALS INDUSTRY	327
DEFINITIONS	327
<i>Performance and Speciality chemicals</i>	329
<i>Pharmaceutical Fine Chemicals</i>	330
MARKET SIZE.....	331
MARKET STRUCTURE.....	332
<i>North America</i>	334
<i>Europe</i>	334
<i>Asia</i>	335
MARKET TRENDS	337
<i>Market drivers</i>	340
<i>Market Barriers</i>	340
MAIN PLAYERS	341
OVERVIEW OF GLOBAL COSMETICS INDUSTRY	350
MARKETS AND TRENDS	350
MAIN PLAYERS	354
<i>10 companies</i>	
REGULATORY.....	361
<i>Regulation of Cosmetics in the EU</i>	361
<i>Regulation of Cosmetics in the USA</i>	363
<i>Regulation of Cosmetics in Canada</i>	366
<i>Regulation of Cosmetics in Japan</i>	367
OVERVIEW OF GLOBAL DIETARY SUPPLEMENT INDUSTRY	369
DIETARY SUPPLEMENTS.....	369
<i>Definitions</i>	370
<i>Product Categories</i>	370
<i>Distribution Channels</i>	374
<i>Market Structure</i>	376
<i>Product and Brand Differentiation</i>	377
MARKETS AND TRENDS	377
<i>Market Drivers</i>	379
<i>Success Factors</i>	380
<i>Barriers to Entry</i>	381
MAIN PLAYERS	382
<i>US</i>	382
<i>EU</i>	386
REGULATORY.....	387
<i>US</i>	387
<i>EU</i>	391

Volume 2

NEWS.....	393
<i>40 items</i>	
CONTACT REPORTS.....	451
ACADEMIA	451
<i>9 contacts</i>	
CHEMICAL MANUFACTURERS, PROCESSORS AND TRADERS	457
<i>27 companies</i>	
PHARMACEUTICAL INDUSTRY	519
<i>10 companies</i>	
COSMETIC INDUSTRY	528
<i>19 companies</i>	
FINE CHEMICAL INDUSTRY	550
<i>13 companies</i>	
DIETARY SUPPLEMENT INDUSTRY	561
<i>21 companies</i>	

TABLES

TABLE 1	OVERVIEW OF THE POTENTIAL MARKET FOR TRITERPENE DERIVATIVES IN PHARMACEUTICALS	67
TABLE 2	OVERVIEW OF POTENTIAL PARTNERS IN THE PHARMACEUTICAL INDUSTRY	76
TABLE 3	SALES OF ANTI-HIV DRUGS, 2005.....	85
TABLE 4	COSTS INVOLVED IN HIV TREATMENT, 2006	87
TABLE 5	MARKET SIZE AND ESTIMATED GROWTH FOR ONCOLOGY TREATMENTS, 2004-2010	90
TABLE 6	SALES OF TOP 20 CANCER TREATMENTS IN MAJOR PHARMACEUTICAL MARKETS, 2004	90
TABLE 7	CANCER INCIDENCE RATES IN THE US BY RACE AND SEX, 2006.....	93
TABLE 8	ESTIMATES OF CANCER PREVALENCE IN 17 (*) EUROPEAN COUNTRIES, 2002.....	94
TABLE 9	THE 10 CANCERS WITH THE HIGHEST MORTALITY IN 38 (*) EUROPEAN COUNTRIES, 1998.....	94
TABLE 10	THE EARLY STAGES OF MALIGNANT MELANOMA	97
TABLE 11	THE LATTER STAGES OF MALIGNANT MELANOMA.....	98
TABLE 12	GLOBAL MELANOMA STATISTICS OVERVIEW (FEMALES)	101
TABLE 13	GLOBAL MELANOMA STATISTICS OVERVIEW (MALES).....	101
TABLE 14	GLOBAL INCIDENCE AND PREVALENCE OF MALIGNANT MELANOMA, 2002	102
TABLE 15	MALIGNANT MELANOMA PREVALENCE IN THE UNITED STATES (1 ST JAN 2002)	107
TABLE 16	NUMBERS AND RATES OF MALIGNANT MELANOMA IN THE UK, 2002.....	108
TABLE 17	INCIDENCE OF ACTINIC KERATOSIS	114
TABLE 18	SALES OF DRUGS AGAINST HERPES VIRUSES, 2000-2005	116
TABLE 19	SALES OF LABIAL HERPES DRUGS, \$M (2004-2005).....	116
TABLE 20	ESTIMATED PRICE AND COST FOR PRESCRIBABLE HERPES TREATMENTS	119
TABLE 21	PRICE COMPARISON OF GENERIC ACYCLOVIR DRUGS	119
TABLE 22	HERPES DIAGNOSES AT GUM CLINICS IN THE UK, 1995-2004.....	121
TABLE 23	INTEREST FROM POTENTIAL PARTNERS IN THE COSMETICS INDUSTRY.....	133
TABLE 24	MAIN CURRENT USES OF TRITERPENE EXTRACTS IN DIETARY SUPPLEMENTS	187
TABLE 25	INTEREST FROM POTENTIAL PARTNERS IN THE DIETARY SUPPLEMENT INDUSTRY.	189
TABLE 26	INTEREST FROM POTENTIAL PARTNERS IN THE FINE CHEMICAL INDUSTRY.	208
TABLE 27	MANUFACTURERS AND PROCESSORS OF BETULIN, LISTED BY PRICE OF PRODUCT	215
TABLE 28	MANUFACTURERS AND PROCESSORS OF BETULINIC ACID, LISTED BY PRICE OF PRODUCT	217
TABLE 29	GLOBAL MANUFACTURERS AND PROCESSORS OF LUPEOL, LISTED BY PRICE OF PRODUCT	219
TABLE 30	OVERVIEW OF PATENTS FILED BY NATURNORTH.....	230
TABLE 31	GLOBAL PHARMACEUTICAL MARKET, \$B (2000-2010)	263
TABLE 32	SIZE OF THE PHARMACEUTICAL MARKET, 1985-1999, \$B	275
TABLE 33	LARGEST PHARMACEUTICAL MARKETS (1989-1999), \$M	275
TABLE 34	MARKET CONSOLIDATION IN THE GLOBAL PHARMACEUTICAL INDUSTRY	277
TABLE 35	THE EU PHARMACEUTICAL INDUSTRY IN FIGURES (2004).....	295
TABLE 36	RESEARCH AND DEVELOPMENT IN THE EU PHARMACEUTICAL INDUSTRY (2004).....	295
TABLE 37	THE PHARMACEUTICAL MARKET IN EUROPE, €B (2003)	296
TABLE 38	THE GERMAN PHARMACEUTICAL BASIC SUBSTANCES MARKET, €B (2004).....	299
TABLE 39	MARKET SIZE OF THE ITALIAN PHARMACEUTICAL MARKET \$M (2004)	313
TABLE 40	ITALIAN IMPORT AND EXPORT OF PHARMACEUTICALS (2004).....	314
TABLE 41	MARKET SIZE FOR THE BRAZILIAN PHARMACEUTICAL INDUSTRY, \$M (2004-2006)	323
TABLE 42	MARKET SIZE FOR THE CHILEAN PHARMACEUTICAL INDUSTRY, \$M (2003-2005).....	324
TABLE 43	DEFINITIONS OF TERMS USED IN THE FINE CHEMICAL INDUSTRY	330
TABLE 44	TYPES AND NUMBERS OF FINE CHEMICAL COMPANIES	332
TABLE 45	CUSTOMERS OF THE FINE CHEMICALS INDUSTRY	333
TABLE 46	GLOBAL VALUE OF AMINO ACIDS IN SYNTHESIS APPLICATIONS THROUGH 2009 (\$M)	334
TABLE 47	RECENT ACTIVITY IN THE FINE CHEMICALS INDUSTRY	339
TABLE 48	TOP 10 COMPANIES IN THE FINE CHEMICALS INDUSTRY	341
TABLE 49	COSMETIC PRODUCT CATEGORY WITH GREATEST GROWTH BY REGION, 2004-2005	353
TABLE 50	THE GLOBAL TOP 10 PLAYERS IN THE COSMETICS AND TOILETRIES MARKET, 2006.....	354
TABLE 51	LIST OF DIETARY SUPPLEMENT PRODUCT CATEGORIES.....	370
TABLE 52	THE MOST COMMON DIETARY SUPPLEMENTS AND ITS BENEFITS.....	372
TABLE 53	MARKET CONCENTRATION IN THE DIETARY SUPPLEMENT INDUSTRY IN THE US	376
TABLE 54	US DIETARY SUPPLEMENT MARKET BY MANUFACTURER / MARKETER.....	376
TABLE 55	ESTIMATED DIETARY SUPPLEMENT MARKET SIZE BY PRODUCT CATEGORY IN US, 2001	561

FIGURES

FIGURE 1 CHEMICAL STRUCTURE OF ISOPRENE.....	31
FIGURE 2 CHEMICAL STRUCTURE OF SQUALENE	32
FIGURE 3 CHEMICAL STRUCTURE OF LUPEOL.....	32
FIGURE 4 CHEMICAL STRUCTURE OF BETULIN	33
FIGURE 5 CHEMICAL STRUCTURE OF BETULINIC ACID.....	33
FIGURE 6 A TWO-STEP SYNTHETIC SCHEME FOR THE PREPARATION OF BETULINIC ACID FROM BETULIN	35
FIGURE 7 A FIVE-STEP SYNTHETIC SCHEME FOR THE PRODUCTION OF BETULINIC ACID FROM BETULIN	35
FIGURE 8 ANTI CANCER ACTIVITY OF BETULINIC ACID AND SEVERAL OF ITS DERIVATIVES.	46
FIGURE 9 ANTI-HIV-1 ACTIVITY OF BETULINIC ACID AND SEVERAL OF ITS DERIVATIVES	51
FIGURE 10 THE BETULIN DERIVATIVE, IC9564, AN ANTI-ENTRY ACTIVE HIV DRUG	53
FIGURE 11 A BI-FUNCTIONAL DRUG WITH CLINICAL POTENTIAL.....	57
FIGURE 12 SURVIVAL CURVE FOR MELANOMA STAGE IV	105
FIGURE 13 WORLD AGE-STANDARDISED INCIDENCE RATES OF MALIGNANT MELANOMA, 2002.....	106
FIGURE 14 PERCENTAGE DISTRIBUTION OF MALIGNANT MELANOMA ON PARTS OF YOUR BODY	106
FIGURE 15 EUROPEAN AGE-STANDARDISED INCIDENCE RATES OF MALIGNANT MELANOMA, 2002.....	108
FIGURE 16 AGE SPECIFIC INCIDENCE RATES FOR MALIGN MELANOMA IN THE UK, 2002	109
FIGURE 17 INCIDENCE AND MORTALITY OF MALIGNANT MELANOMA IN GREAT BRITAIN, 1975-2003	109
FIGURE 18 INCIDENCE RATES OF MALIGNANT MELANOMA FOR MEN IN GREAT BRITAIN, 1975-2002	110
FIGURE 19 INCIDENCE RATES OF MALIGNANT MELANOMA FOR WOMEN IN GREAT BRITAIN, 1975-2002	110
FIGURE 20 GENITAL HERPES - INITIAL VISITS TO PHYSICIANS' OFFICES: UNITED STATES, 1966-2004.....	120
FIGURE 21 COST OF DEVELOPING A NEW MEDICINE (1979 - 2003).....	268
FIGURE 22 DEVELOPMENT OF A DRUG FROM TARGET IDENTIFICATION TO POST-LAUNCH PRODUCT REVIEW	271
FIGURE 23 NEW MOLECULAR ENTITIES APPROVED IN THE US, 1996–2003	271
FIGURE 24 SUCCESS RATES IN DRUG DEVELOPMENT.....	273
FIGURE 25 PERCENTAGE MARKET SHARE FOR PRODUCTS LAUNCHED IN THE LAST FIVE YEARS (2003).....	275
FIGURE 26 PHARMACEUTICAL INDUSTRY EXPENDITURE IN R&D IN EUROPE (2002)	296
FIGURE 27 SPLIT OF EUROPEAN PHARMACEUTICAL MARKET (2004)	297
FIGURE 28 FUNDING OF HEALTH-RELATED R&D IN THE UK	304
FIGURE 29 COMPARISON OF SHARE OF GLOBAL PHARMACEUTICAL R&D INVESTMENT	304
FIGURE 30 FINE CHEMICALS BREAKDOWN BY TARGET SECTORS.....	328
FIGURE 31 BREAKDOWN OF FINE CHEMICALS BY PRODUCTION TYPE.....	329
FIGURE 32 GLOBAL SALES OF COSMETICS AND TOILETRIES (1999-2005)	351
FIGURE 33 COSMETICS AND TOILETRIES MARKET PERFORMANCE BY REGION, 2006.....	351
FIGURE 34 SALES PER PRODUCT CATEGORY IN THE COSMETIC INDUSTRY, 2005	352
FIGURE 35 GLOBAL GROWTH PER PRODUCT CATEGORY IN THE COSMETIC INDUSTRY, 2004-2005.....	353
FIGURE 36 US DIETARY SUPPLEMENT SALES BY MARKET CHANNEL	375
FIGURE 37 US DIETARY SUPPLEMENT MARKET BY CATEGORY	378